Almorexant: Dual orexin OX1/OX2 antagonist treatment of sleep disorders

Drugs of the Future

Volumn 34, Issue 1, 2009, Pages 5-10

  Owen, R T ^a   Castaner R ^a   Bolos J ^a   Estivill, C ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 METHYL 6 BENZOXAZOLYL) 3 (1,5 NAPHTHYRIDIN 4 YL)UREA; 1 (6,8 DIFLUORO 2 METHYL 4 QUINOLINYL) 3 (4 DIMETHYLAMINOPHENYL)UREA; ACT 078573; ALMOREXANT; JNJ 10397409; OREXIN; OREXIN 1 RECEPTOR; OREXIN 2 RECEPTOR; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG; ZOLPIDEM;

ATTENTION DISTURBANCE; BLOOD PRESSURE; CLINICAL TRIAL; COORDINATION DISORDER; CORTICOTROPIN BLOOD LEVEL; DIPLOPIA; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERANCE; EVENING DOSAGE; FATIGUE; GROWTH HORMONE BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; HYDROCORTISONE BLOOD LEVEL; INSOMNIA; LUTEINIZING HORMONE BLOOD LEVEL; MORNING DOSAGE; NONHUMAN; PROLACTIN BLOOD LEVEL; REM SLEEP; REVIEW; SENSORIMOTOR FUNCTION; SIDE EFFECT; SLEEP DISORDER; SLEEP INDUCTION; SLEEP TIME; SOMNOLENCE; TESTOSTERONE BLOOD LEVEL; THYROTROPIN BLOOD LEVEL; TREATMENT DURATION; TREATMENT OUTCOME; XEROSTOMIA;

EID: 68249099216     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2009.034.01.1324392     Document Type: Review

References (19)

1. Weller, T., Koberstein, R., Aissaoui, H., Clozel, M., Fischli, W. (Actelion Pharmaceuticals Ltd.). Substituted 1,2,3,4-tetrahydroisoquinoline derivatives. EP1751111, JP 2007525531, US 2007191424, WO 2005118548.
2. Silber, M.H. Clinical practice. Chronic insomnia. New Engl J Med 2005, 353(8): 803-10.
3. Wilson, S., Nutt, D. Drug treatment of chronic insomnia - Dawn at the end of a long night. J Psychopharmacol 2008, 22(7): 703-6.
4. Owen, R.T. Ramelteon: Profile of a new sleep-promoting medication. Drugs Today 2006, 42(4): 255-63.
5. Sakurai, T., Amemiya, A., Ishii, M. et al. Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behaviour. Cell 1998, 92(4): 573-85.
6. de Lecea, L., Kilduff, T.S., Peyron, C et al. The hypocretins: Hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA 1998, 95(1): 322-7.
7. Smith, M.J., Piper, D.C., Duxon, M.S., Upton, N. Evidence implicating a role for orexin-1 receptor modulation of paradoxical sleep in the rat. Neurosci Lett 2001, 341(3): 256-8.
8. Willie, J.T., Chemelli, R.M., Sinton, C.M. et al. Distinct narcolepsy syndromes in orexin receptor-2 and orexin-null mice: Molecular genetic dissection of non-REM and REM regulatory processes. Neuron 2003, 38(5): 715-30.
9. Brisbare-Roch, C., Dingemanse, J., Koberstein, R. et al. Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med 2007, 13(2): 150-5.
10. Brisbare-Roch, C., Lely, F., Ralf, K., Oliver, N., Francois, J. Transient orexin receptor blockade induces sleep without cataplexy in rats. Sleep Biol Rhythms [5th World Congr World Fed Sleep Res Sleep Med Soc (Sept 2-6, Cairns) 2007] 2007, 5(Suppl. 1): Abst PO270 (A78).
11. Brisbare-Roch, C., Clozel, M., Jenck, F. Effects of repeated oral administration of the orexin receptor antagonist almorexant in male rats and dogs. Sleep [22nd Annu Meet Assoc Sleep Soc (June 7-12, Baltimore) 2008] 2008, 31(Suppl.): Abst 0118 (A38).
12. Jenck, F., Fischer, C., Qiu, C., Hess, P., Kolberstein, R., Brisbare-Roch, C. Somnolence induced by pharmacological blockade of both orexin 0X1 and 0X2 receptors in dogs. Sleep Biol Rhythms [5th World Congr World Fed Sleep Res Sleep Med Soc (Sept 2-6, Cairns) 2007] 2007, 5: Abst P0271(A79).
13. Dugovic, C., Shelton, J., Sutton, S. et al. Sleep-inducing effects mediated by selective blockade of orexin 0X2 receptors during the light phase in the rat. Sleep [22nd Annu Meet Assoc Sleep Soc (June 7-12, Baltimore) 2008] 2008, 31(Suppt.): Abst 0101 (A33).
14. Hoever, P., de Haas, S., Winkler, J., Cavallaro, M., van Gerven, J., Dingemanse, J. Entry-into-humans study with ACT-078573, a dual orexin receptor antagonist: Tolerability, safety and pharmacokinetics. Sleep Biol Rhythms [5th World Congr World Fed Sleep Res Sleep Med Soc (Sept 2-6, Cairrns) 2007] 2007, 5(Suppl.): Abst P0444 (A131).
15. Hoever, P., de Haas, S., Chiossi, E., van Gerven, J., Dingemanse, J. Multiple-dose pharmacokinetics, pharmacodynamics, safety and tolerability of the orexin receptor antagonist almorexant in healthy subjects. Sleep [22nd Annu Meet Assoc Sleep Soc (June 7-12, Baltimore) 2008] 2008, 31(SuppL): Abst 0116 (A38).
16. Dingemanse, J., Dorffner, G., Hajak, G. et al. Proof-of-concept study in primary insomnia patients with ACT-078573, a dual orexin receptor antagonist. Sleep Biol Rhythms [5th World Congr World Fed Sleep Res Sleep Med Soc (Sept 2-6, Cairns) 2007] 2007, 5(Suppl.): Abst P0653 (A194).
17. Hoever, P., de Haas, S., Chiossi, E., van Gerven, J., Dingemanse, J. Entry-into-humans study of ACT-078573, a dual orexin receptor antagonist: Pharmacodynamics. Sleep Biol Rhythms [5th World Congr World Fed Sleep Res Sleep Med Soc (Sept 2-6, Cairns) 2007] 2007, 5(SuppL): Abst P0443 (A131).
18. ACT-07853 in elderly subjects with chronic primary insomnia (NCT00606593). ClinicalTrials.gov Web site, February 9, 2009.
19. Almorexant in adult subjects with chronic primary insomnia (RESTORA 1) (NCT00608985). ClinicalTrials.gov Web site, February 9, 2009.